Verrica Pharmaceuticals Inc. Shareholders' Equity
Verrica Pharmaceuticals Inc. (VRCA) had Shareholders' Equity of $4.31 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-06
- 2026-06-30: Stockholders' Equity Attributable to Parent $4.31M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $16.05M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $24.74M.
- 2025-09-30: Stockholders' Equity Attributable to Parent -$17.04M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $4.31M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $16.05M 10-Q · filed 2026-08-06 |
| 2025-12-31 | $24.74M 10-Q · filed 2026-08-06 |
| 2025-09-30 | -$17.04M 10-Q · filed 2025-11-14 |
| 2025-06-30 | -$17.48M 10-Q · filed 2026-08-06 |
| 2025-03-31 | -$18.58M 10-Q · filed 2026-08-06 |
| 2024-12-31 | -$9.86M 10-Q · filed 2026-08-06 |
| 2024-09-30 | -$34.05M 10-Q · filed 2025-11-14 |
| 2024-06-30 | -$13.30M 10-Q · filed 2025-11-14 |
| 2024-03-31 | $1.51M 10-Q · filed 2025-11-14 |
| 2023-12-31 | $19.76M 10-K · filed 2026-03-11 |
| 2023-09-30 | $42.30M 10-Q · filed 2024-11-05 |
| 2023-06-30 | $55.40M 10-Q · filed 2024-11-05 |
| 2023-03-31 | $64.85M 10-Q · filed 2024-11-05 |
| 2022-12-31 | $40.03M 10-K · filed 2025-03-11 |
| 2022-09-30 | $44.77M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $16.33M 10-Q · filed 2023-11-09 |
| 2022-03-31 | $25.42M 10-Q · filed 2023-11-09 |
| 2021-12-31 | $32.60M 10-K · filed 2024-02-29 |
| 2021-09-30 | $40.85M 10-Q · filed 2022-11-07 |
| 2021-06-30 | $52.16M 10-Q · filed 2022-11-07 |
| 2021-03-31 | $61.81M 10-Q · filed 2022-11-07 |
| 2020-12-31 | $32.99M 10-K · filed 2023-03-06 |
| 2020-09-30 | $39.18M 10-Q · filed 2021-11-12 |
| 2020-06-30 | $48.46M 10-Q · filed 2021-11-12 |
| 2020-03-31 | $56.61M 10-Q · filed 2021-11-12 |
| 2019-12-31 | $65.02M 10-K · filed 2022-03-02 |
| 2019-09-30 | $71.65M 10-Q · filed 2020-11-09 |
| 2019-06-30 | $76.84M 10-Q · filed 2020-11-09 |
| 2019-03-31 | $82.76M 10-Q · filed 2020-11-09 |
| 2018-12-31 | $89.43M 10-K · filed 2021-03-17 |
| 2018-09-30 | $96.35M 10-Q · filed 2019-11-06 |
| 2018-06-30 | $101.59M 10-Q · filed 2019-11-06 |
| 2018-03-31 | -$8.75M 10-Q · filed 2019-11-06 |
| 2017-12-31 | -$7.04M 10-K · filed 2020-03-13 |
| 2016-12-31 | -$2.66M 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |